Boston Scientific Corporation
) recently revealed that it has received CE Mark approval and is
proceeding with the full European market launch of the Ranger
Paclitaxel-Coated PTA Balloon Catheter.
According to Boston Scientific, this new and advanced
Drug-Coated Balloon (DCB) catheter will enrich the company's
portfolio of peripheral vascular disease products besides
strengthening the company's foothold in Europe.
The Ranger DCB is an additional option for the treatment of
peripheral artery disease (PAD). It delivers an anti-stenotic drug
to the unhealthy vascular tissue while leaving behind no permanent
implant. Further, it offers a radical option to treat both
above-the-knee and below-the-knee lesions.
According to a reliable source, in using traditional
technologies, physicians end up losing a significant portion of
drug coating during the handling, insertion and placement of the
device. The Ranger DCB is so designed as to reduce pertinent drug
loss while optimizing both deliverability and the absorption of the
drug in the targeted tissue.
Notably, PAD is a circulatory disorder resulting from a build-up
of plaque in one or more arteries, most often in the legs. With the
aggravation of PAD in a patient, plaque accumulation may reduce
blood flow through the arteries significantly. This may result in
pain and increasing disability with severe cases even leading to
amputation of the affected limb.
In recent times, PAD has become a major cause of worry all over
the world. As per recent data, at present, 12−14% of the general
population is affected by PAD. Boston Scientific, which has
become a forerunner with its advanced drug-eluting technologies, is
thus upbeat about the recent European approval of the Ranger DCB
which it expects as having the potential to capture significant
market share in this geography.
The Peripheral Interventions (PI) business of Boston Scientific
has continuously delivered above-market growth in the last few
quarters driven by strong international and emerging market
performance. According to the company, this consistent success is
driven by its leadership positions in balloons, stents and
Growth in the U.S. is also encouraging on the back of the Epic
stent (a self-extending Nitinol stent ideal for the iliac's,
launched in 2012), the carotid wall stent, and the direction
micro-catheter for the delivery of diagnostic or therapeutic
material, which was launched in the fourth quarter of 2013.
Other Stocks to Consider
Boston Scientific currently carries a Zacks Rank #3 (Hold). Some
better-ranked stocks in the broader medical sector that look
promising at the moment are
Intuitive Surgical, Inc.
). While MASI sports a Zacks Rank #1 (Strong Buy), the other two
stocks carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
BOSTON SCIENTIF (BSX): Free Stock Analysis
INTUITIVE SURG (ISRG): Free Stock Analysis
HOLOGIC INC (HOLX): Free Stock Analysis Report
MASIMO CORP (MASI): Free Stock Analysis Report
To read this article on Zacks.com click here.